Stay updated with breaking news from Pathogenesis Readiness. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
MIT chemists have come up with a new way to identify neutralizing antibodies against SARS-CoV-2 in a blood sample, by analyzing how the antibodies interact with sugar molecules found on the surface of the virus’ spike protein.
The FINANCIAL — An additional “booster” dose of Moderna or Pfizer mRNA-based vaccine is needed to provide immunity against the Omicron variant of SARS-CoV-2, the virus that causes COVID-19, according to a study by researchers at the Ragon Institute of MGH, MIT and Harvard. The results of this study, reported in the journal Cell, indicate that traditional dosing regimens of COVID-19 vaccines available in the United States do not produce antibodies capable of recognizing and neutralizing the Omicron variant. In late November, health officials in South Africa reported that a previously unkn...
SUMMARY Vaccination elicits immune responses capable of potently neutralizing SARS-CoV-2. However, ongoing surveillance has revealed the emergence of variants harboring mutations in spike, the main target of neutralizing antibodies. To understand the impact of these variants, we evaluated the neutralization potency of 99 individuals that received one or two doses of either BNT162b2 or mRNA-1273 vaccines against pseudoviruses representing 10 globally circulating strains of SARS-CoV-2. Five of the 10 pseudoviruses, harboring receptor-binding domain mutations, including K417N/T, E484K, and N501Y...